Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259789 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT03259789: Completed Phase 3 study, sponsored by Theracos.
NCT03259789 is a Phase 3 study that has completed, run by Theracos. The registered enrollment target is 351 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259789, a Phase 3 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Primary Outcome
HbA1c was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.
Interventions
- DRUG Bexagliflozin tablets, placebo
- DRUG Bexagliflozin tablets, 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 3 |
What the finished NCT03259789 record still lists
NCT03259789 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Bexagliflozin tablets, placebo is the first listed.
NCT03259789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259789 about?
NCT03259789 is a clinical study titled "Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects". The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT03259789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2017-11-28. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT03259789?
The interventions under investigation include: Bexagliflozin tablets, placebo (DRUG), Bexagliflozin tablets, 20 mg (DRUG).
Who is sponsoring clinical trial NCT03259789?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259789's enrollment target sits among peer trials
351 1033rd of 2000 higher than 967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI